공시 • Apr 23
Sirona Biochem Corp. announced that it expects to receive CAD 0.4 million in funding Sirona Biochem Corp. announced a non-brokered private placement that it will issue up to 400 unsecured convertible debentures units at an issue price of CAD 1,000 per unit for the gross proceeds of up to CAD 400,000 on April 22, 2025. Each Debenture Unit will have a face value of of CAD 1,120, consisting of CAD 1,000 in principal and CAD 120 in prepaid interest. The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, and such accrued interest will be paid semi-annually, in arrears. At the election of the Company, Prepaid Interest and Accrued Interest may be paid in cash or converted into Shares at a conversion price equal to the maximum Discounted Market Price equal to the maximum Discounted Market Price. The holder may, at its option, convert in full or in part, the Principal at any time prior to the maturity date, being the third anniversary of the issue date, into units of the Company at CAD 0.10 per Unit. Upon conversion of the Principal, Prepaid Interest and unpaid Accrued Interest, will be, at the election of the Company, either paid in cash or converted into Shares at the Interest Conversion Price. Each Unit will consist of one Share and one non-transferable share purchase warrant. Each Unit will consist of one Share and one non-transferable share purchase warrant at an exercise price of CAD 0.15 at any time prior to the Maturity Date. The Company shall have the right to redeem the Convertible Debentures prior to the Maturity Date at any time after 6 months from the issue date, by paying holders in cash the Face Value of the Convertible Debentures, together with all Prepaid and Accrued Interest and a redemption penalty payment of 8% of the Face Value. The closing of the Offering is subject to the receipt of necessary regulatory approvals, including the approval of the TSXV. The Convertible Debentures, Shares, Warrants and any Warrant Shares will be subject to a four month hold period under applicable securities laws and TSXV policies. The Company may pay eligible finders a fee in connection with the Offering. 공시 • Apr 22
Sirona Biochem Corp. announced that it expects to receive CAD 3 million in funding from Promura GmbH Sirona Biochem Corp. announced that it has entered into a investment agreement with Promura GmbH to issue unsecured convertible debentures for gross proceeds of CAD 3,000,000 on April 22, 2025. The debentures will accrue interest at the rate of 12%. The company plans to compensate finders by way of cash fees and warrants. The completion of the private placement is subject to customary conditions, including acceptance from the Toronto stock exchange venture. All securities issued will be subject to a hold period in accordance with TSXV and/or other regulatory requirements. New Risk • Jan 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.2m (US$9.13m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Negative equity (-CA$3.5m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.2m market cap, or US$9.13m). New Risk • Oct 30
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.0m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (37% average weekly change). Negative equity (-CA$3.5m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.0m market cap, or US$9.38m). Minor Risk Shareholders have been diluted in the past year (3.4% increase in shares outstanding). New Risk • Sep 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Negative equity (-CA$3.1m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Market cap is less than US$100m (CA$16.8m market cap, or US$12.4m). New Risk • Jun 23
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CA$3.1m). Revenue is less than US$1m. Market cap is less than US$10m (CA$12.8m market cap, or US$9.36m). 